The customer stated that they received erroneous results for one patient sample tested for elecsys ft3 iii (ft3) and the elecsys ft4 ii assay (ft4) on a cobas 8000 e 602 module (e602).It was asked, but it is not known if the erroneous results were reported outside of the laboratory.This medwatch concerns the ft4 assay.Please refer to the medwatch with patient identifier (b)(6) for information related to the ft3 assay.The customer collected the sample on (b)(6) 2017 and it was tested on their e602 analyzer on (b)(6) 2017.The sample was then provided for investigation, where it was tested on a second e602 analyzer and a cobas e 411 immunoassay analyzer (e411).No adverse events were alleged to have occurred with the patient.The serial number of the e602 analyzer used at the customer site was asked for, but not provided.The serial number of the e602 analyzer used for investigation was (b)(4).The ft4 reagent lot number 265631, with an expiration date of september 2018 was used on this analyzer.The serial number of the e411 analyzer used for investigation was (b)(4).The ft4 reagent lot number 265631, with an expiration date of september 2018 was used on this analyzer.Calibration and quality control recoveries related to investigation testing were ok.The ft4 values generated at the customer site and during investigations are considerably different.The ft4 value generated at the customer site may represent either a non-reproducible low result or a non-reproducible high result.Further investigation of the difference in ft4 values was not possible based on the provided information.Further investigation also was not possible since there was no remaining sample volume available.Based on the similarity of ft3 and tsh values generated at the customer site and during investigations, a sample mix up can most likely be excluded.Based on the information provided, a general reagent issue can most likely be excluded.
|